Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
- Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study
- FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome
Read more at globenewswire.comNASDAQ:QNRX (11/7/2025, 8:10:47 PM)
9.01
+0.44 (+5.13%)
Find more stocks in the Stock Screener
